Trial report in American journal of physiology. Endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Michael R RickelsDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States.ORCID 0000-0002-9253-838X
Melena D BellinDivision of Pediatric Endocrinology, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, United States.ORCID 0000-0002-7324-4837
Darko StefanovskiDepartment of Biostatistics, University of Pennsylvania School of Veterinary Medicine, Kennett Square, Pennsylvania, United States.ORCID 0000-0002-4654-0569
Amy J PeleckisDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States.
Cornelia Dalton-BakesDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States.
Eileen MarkmannDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States.
Huong-Lan NguyenDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States.
Raymond R TownsendDivision of Nephrology and Hypertension, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States.ORCID 0000-0002-3215-9118
Bernhard J HeringSchulze Diabetes Institute, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, United States.
Ali NajiDivision of Transplant Surgery, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States.
Funding
Univ of Pennsylvania Diabetes Endocrinology Res CTRP30DK019525 · UNIVERSITY OF PENNSYLVANIA · 1986 to 2025
$10.9M
Institutional Clinical and Translational Science AwardUL1TR001878 · UNIVERSITY OF PENNSYLVANIA · 2025 to 2025
$10.2M
Clinical and Translational Science AwardUL1TR001873 · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$10.0M
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) P30 DK19525NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR001878NIDDK NIH HHS P30 DK019525NIDDK NIH HHS R01 DK091331
6 · The paper itself
Abstract
Type 1 diabetes recipients of intrahepatic islet transplantation exhibit glucose-dependent suppression of insulin and activation of glucagon secretion in response to insulin-induced hypoglycemia associated with clinical protection from hypoglycemia. Whether sympathetic activation of adrenergic receptors on transplanted islets is required for these responses in defense against hypoglycemia is not known. To evaluate the adrenergic contribution to posttransplant glucose counterregulation, we performed a randomized, double-blind crossover study of responses during a hyperinsulinemic euglycemic-hypoglycemic clamp under phentolamine (α-adrenergic blockage), propranolol (β-adrenergic blockage), or placebo infusion. Characteristics of participants (5 females/4 males) were as follows: median (range) age 53 (34-63) yr, diabetes duration 29 (18-56) yr, posttransplant 7.0 (1.9-8.4) yr, HbA
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
α- or β-Adrenergic blockade does not affect transplanted islet cell responses to hypoglycemia in type 1 diabetes. · full record | Socratic